Future-Proofing the Pharma Customer & Supplier Relationship

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

Continuous adaption
Evolving US tariff/trade policy is but one of the many variables that bio/pharmaceutical companies and their suppliers are facing. Global supply chains are always subject to geopolitical uncertainties, fluctuating economic conditions, and changes in trade and government policies, but the pace of that change has accelerated. Add to that the base challenge of increased product and supply chain complexity in the industry, and the need for bio/pharma companies and their suppliers to adapt is ever more important for supply assurance.

Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer

An executive panel at the DCAT Week program, Future-Proofing the Pharma Customer–Supplier Relationship, will share lessons learned, best practices, and innovative ways on how they are collaborating to enhance supply-chain visibility and resilience, mitigate risk, and optimize supply planning now and for what may lie ahead.

Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb

Participating in the panel of are:  Xavier De Ceuninck, Category Management Lead, PGS Global Procurement, Source to Pay, Pfizer; Emad Abdelsadek, Vice President, Sales, EMEA, BD Biopharma Systems; Troy Mathews, Executive Director, Direct Materials Strategic Sourcing, Supplier Management & Site Operations, Global Procurement – Global Product Development & Supply, Bristol Myers Squibb; and Sara Henneman, Vice President and General Manager, Cell Culture and Cell Therapy, Thermo Fisher Scientific. The panel will be moderated by Vishal Bhandari, Partner, Healthcare & Life Sciences Practice, Americas, Kearney.

The program, Future-Proofing the Pharma Customer–Supplier Relationship, is part of DCAT Week, the premier gathering for companies engaged in the global bio/pharmaceutical business ecosystem, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). DCAT Week will be held March 23–26, 2026, in New York. The program, Future-Proofing the Pharma Customer–Supplier Relationship, will be held on Tuesday March 24, 2026, 11:00 AM–12:00 PM. Further information, including how to register, may be found here. The program is exclusive to DCAT Member Companies.

Recent Feature Articles

Small-Molecule CDMO Outlook: What Lies Ahead

By
At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing

Biotech IPOs: Who Is Topping the Class of 2026?

By
What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…

China: The Innovation Factor Coming Into Play

By
Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?

Oncology Drug Market: The Ups and Downs 

By
ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?